title: A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer.
abstract: We have compared mutation analysis by Amplification Refractory Mutation System (ARMS) and epidermal growth factor receptor (EGFR) mutant-specific antibodies for their ability to detect two common activating EGFR mutations in a cohort of 115 advanced non-small cell lung cancer (NSCLC), including cytology material, core biopsy, and bronchoscopic biopsies. Assessment of EGFR mutation status was performed by using antibodies and ARMS assay specific to the two major forms of mutant EGFR, exon 19 deletion E746-A750 (c.2235_2249del15 or c.2236_2250del15, p. Glu746_Ala750 del) and exon 21 L858R point mutation (c.2573T>G, p.Leu858Arg). In this study the optimal buffer for antigen retrieval was sodium citrate (pH 6.0). Q score was used to evaluate the specific mutant EGFR proteins expression. Validation using clinical material showed deletions in exon 19 were detected in 19.1% and L858R mutation in 20% of all cases by ARMS assay. A cutoff value of score 1 was used as positive by IHC. No wild type cases were immuno-reactive. The antibodies performed well in cytology, core biopsies and bronchoscopic biopsies. There were only one false positive case using L858R IHC (sensitivity 100%, specificity 98.5%, positive predictive value 96%, negative predictive value 100%). All 23 E746-A750 exon 19 deletions identified by mutation analysis were positive by IHC. The sensitivity of exon 19 IHC for E746-A750 was 100%, specificity 100%, positive predictive value 100% and negative predictive value 100%. The result of the IHC stains was finely correlated with mutations status determined by ARMS assay. Although inferior to molecular genetic analysis of the EGFR gene, IHC is highly specific and sensitive for the targeted EGFR mutations. The antibodies are likely to be of clinical value in cases especially where limited tumor material is available, or in situations where molecular genetic analysis is not readily available.
authors.affiliation: Department of Pathology, Southeast University, Zhongda Hospital Nanjing 210009, P.R. China.
authors.forename: Xueqing
authors.initials: X
authors.lastname: Wang
authors.affiliation: Department of Pathology, Southeast University, Zhongda Hospital Nanjing 210009, P.R. China.
authors.forename: Guoqing
authors.initials: G
authors.lastname: Wang
authors.affiliation: Department of Pathology, Southeast University, Zhongda Hospital Nanjing 210009, P.R. China.
authors.forename: Yueyue
authors.initials: Y
authors.lastname: Hao
authors.affiliation: Department of Pathology, Southeast University, Zhongda Hospital Nanjing 210009, P.R. China.
authors.forename: Yinhong
authors.initials: Y
authors.lastname: Xu
authors.affiliation: Department of Pathology, Southeast University, Zhongda Hospital Nanjing 210009, P.R. China.
authors.forename: Lihua
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal; D001706:Biopsy; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics*; D003584:Cytological Techniques; D004252:DNA Mutational Analysis / Q000379:methods*; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D012680:Sensitivity and Specificity
chemical_list: D000911:Antibodies, Monoclonal; D066246:ErbB Receptors
keywords: EGFR mutation; NSCLC; cytology; immunohistochemistry